Evidence map›Paper›PMID 23840407›Full record

ArticlePloS one2013

Designed azolopyridinium salts block protective antigen pores in vitro and protect cells from anthrax toxin.

Christoph Beitzinger, Anika Bronnhuber, Kerstin Duscha, Zsuzsanna Riedl, Markus Huber-Lang, Roland Benz, György Hajós, Holger Barth

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Designing inhibitors of anthrax toxin.Expert opinion on drug discovery · 2014
    Review
  14. Multivalent Inhibitors of Channel-Forming Bacterial Toxins.Current topics in microbiology and immunology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Christoph BeitzingerRudolf-Virchow-Center, DFG-Research Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany.
Anika Bronnhuber
Kerstin Duscha
Zsuzsanna Riedl
Markus Huber-Lang
Roland Benz
György Hajós
Holger Barth
Universität Ulm · DEHUN-REN Research Centre for Natural Sciences · HUUniversity of Würzburg · DEConstructor University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral intracellular acting bacterial protein toxins of the AB-type, which are known to enter cells by endocytosis, are shown to produce channels. This holds true for protective antigen (PA), the binding component of the tripartite anthrax-toxin of Bacillus anthracis. Evidence has been presented that translocation of the enzymatic components of anthrax-toxin across the endosomal membrane of target cells and channel formation by the heptameric/octameric PA63 binding/translocation component are related phenomena. Chloroquine and some 4-aminoquinolones, known as potent drugs against Plasmodium falciparium infection of humans, block efficiently the PA63-channel in a dose dependent way. METHODOLOGY/PRINCIPAL

findingsHere we demonstrate that related positively charged heterocyclic azolopyridinium salts block the PA63-channel in the µM range, when both, inhibitor and PA63 are added to the same side of the membrane, the cis-side, which corresponds to the lumen of acidified endosomal vesicles of target cells. Noise-analysis allowed the study of the kinetics of the plug formation by the heterocycles. In vivo experiments using J774A.1 macrophages demonstrated that the inhibitors of PA63-channel function also efficiently block intoxication of the cells by the combination lethal factor and PA63 in the same concentration range as they block the channels in vitro. CONCLUSIONS/SIGNIFICANCE: These results strongly argue in favor of a transport of lethal factor through the PA63-channel and suggest that the heterocycles used in this study could represent attractive candidates for development of novel therapeutic strategies against anthrax.

Indexed as

AnimalsAnti-Bacterial AgentsAntigens, BacterialBacillus anthracisBacterial ToxinsCell LineCell SurvivalImidazolesLipid BilayersMembrane PotentialsMiceModels, BiologicalProtein BindingProtein TransportPyridinesTitrimetryanthrax toxinAnti-Bacterial AgentsAntigens, BacterialBacterial ToxinsHA 1363HA 1495HA 1568ImidazolesLipid BilayersPyridinesTumor Necrosis Factor-alpha

Identifiers

PMID23840407
PMCPMC3688708
OpenAlexW2061545851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.